Top European Growth Companies With Insider Ownership In August 2026
In August 2026, the European market has been navigating a complex landscape marked by resilient economic data and solid corporate earnings, yet tempered by geopolitical uncertainties and fluctuating energy prices. As investors seek promising opportunities in this environment, growth companies with high insider ownership stand out for their potential alignment of management interests with shareholder value, offering a compelling proposition amid ongoing market volatility.
Top 10 Growth Companies With High Insider Ownership In Europe
| Name | Insider Ownership | Earnings Growth |
| MilDef Group (OM:MILDEF) | 10.3% | 30.9% |
| Kuros Biosciences (SWX:KURN) | 25.9% | 58.6% |
| KebNi (OM:KEBNI B) | 11.8% | 105.2% |
| Gold Road International (OB:GOLDR) | 35.9% | 86% |
| CTT Systems (OM:CTT) | 17.4% | 55.3% |
| Clavister Holding AB (publ.) (OM:CLAV) | 20.5% | 62.4% |
| CD Projekt (WSE:CDR) | 35.2% | 39.6% |
| Bonesupport Holding (OM:BONEX) | 10.6% | 32.2% |
| BioArctic (OM:BIOA B) | 32.2% | 62.3% |
| Bergen Carbon Solutions (OB:BCS) | 11.9% | 52% |
Let's take a closer look at a couple of our picks from the screened companies.
Pharma Mar (BME:PHM)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Pharma Mar, S.A. is a biopharmaceutical company specializing in the research, development, production, and commercialization of bio-active principles for oncology across various international markets including Europe and the United States, with a market cap of €1.42 billion.
Operations: Pharma Mar generates revenue through its focus on oncology-related bio-active principles across markets in Spain, Germany, Ireland, France, Switzerland, the rest of the European Union, and the United States.
Insider Ownership: 12.1%
Earnings Growth Forecast: 37.2% p.a.
Pharma Mar's earnings are projected to grow significantly at 37.2% annually, outpacing the Spanish market. Despite a recent decline in net income from €19.42 million to €0.561 million for H1 2026, analysts expect a stock price increase of 27.1%. The company is trading at 80.4% below its fair value estimate and has received European Commission approval for Zepzelca with atezolizumab as first-line maintenance therapy for small cell lung cancer, enhancing its growth prospects despite high share price volatility.
- Unlock comprehensive insights into our analysis of Pharma Mar stock in this growth report.
- According our valuation report, there's an indication that Pharma Mar's share price might be on the cheaper side.
Swedencare (OM:SECARE)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Swedencare AB (publ) is engaged in the development, manufacturing, marketing, and sale of animal healthcare products for cats, dogs, and horses across North America, Europe, and other international markets with a market cap of approximately SEK3.49 billion.
Operations: The company's revenue segments are divided into Europe (SEK702.30 million), Production (SEK688.80 million), and North America (SEK1.58 billion).
Insider Ownership: 12.8%
Earnings Growth Forecast: 45.6% p.a.
Swedencare's earnings are forecast to grow significantly at 45.6% annually, surpassing the Swedish market's growth rate. Despite a low projected return on equity of 3.5%, the company trades at 77.3% below its estimated fair value, indicating potential undervaluation. Recent insider buying suggests confidence in future prospects, although volumes were modest. Q2 2026 results showed revenue of SEK 672.4 million and net income improvement to SEK 23.7 million from a previous loss, supporting growth potential amidst strategic acquisition pursuits.
- Click here to discover the nuances of Swedencare with our detailed analytical future growth report.
- In light of our recent valuation report, it seems possible that Swedencare is trading behind its estimated value.
Verve Group Media (XTRA:VRV)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Verve Group Media SE is a digital media company that provides ad-software solutions in North America and Europe, with a market cap of €265.75 million.
Operations: The company generates revenue through its Demand Side Platforms (DSP) segment, which accounts for €168.15 million, and its Supply Side Platforms (SSP) segment, contributing €477.89 million.
Insider Ownership: 26.7%
Earnings Growth Forecast: 40% p.a.
Verve Group Media SE, with substantial insider buying and no recent selling, indicates strong internal confidence. Despite being removed from the Germany SDAX Index, it maintains a promising growth trajectory with forecasted annual revenue growth of 10.3%, outpacing the German market average. The company trades significantly below its estimated fair value and is expanding into retail media through innovative mobile ad solutions in Germany. However, interest payments are not well covered by earnings.
- Get an in-depth perspective on Verve Group Media's performance by reading our analyst estimates report here.
- Upon reviewing our latest valuation report, Verve Group Media's share price might be too pessimistic.
Summing It All Up
- Click here to access our complete index of 219 Fast Growing European Companies With High Insider Ownership.
- Curious About Other Options? The end of cancer? These 34 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com